Jefferies Downgrades ZIOPHARM Oncology (ZIOP) to Hold on Increased Risks

December 12, 2012 7:18 AM EST
Get Alerts ZIOP Hot Sheet
Price: $5.78 -4.62%

Rating Summary:
    4 Buy, 10 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 11
Trade ZIOP Now!
Join SI Premium – FREE
Jefferies downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from Buy to Hold with a price target of $4.00 (from $7.00) on increased clinical/regulatory risks.

The firm comments, "ZIOP's lead drug palifosfamide Ph3 data for mSTS is expected in end-1Q13 (vs. YE12 previously). Experts discussions indicate ~40-50% probability for ~3-month PFS benefit; even with ~3-mo PFS benefit, experts view <50% probability for meeting OS endpoint. Additionally, experts view OS benefit likely needed for FDA approval, contrary to ZIOP. Downgrading ZIOP to Hold from Buy on what we view as increased clinical/regulatory risks."

FY13 EPS goes down from ($1.20) to ($1.24).

For an analyst ratings summary and ratings history on ZIOPHARM Oncology click here. For more ratings news on ZIOPHARM Oncology click here.

Shares of ZIOPHARM Oncology closed at $4.44 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst EPS Change, Analyst PT Change, Downgrades, Hot Downgrades

Related Entities

Jefferies & Co

Add Your Comment